naltrexone has been researched along with Weight Gain in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (11.11) | 18.2507 |
| 2000's | 8 (22.22) | 29.6817 |
| 2010's | 15 (41.67) | 24.3611 |
| 2020's | 9 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akerman, S; Citrome, L; Cummings, H; McIntyre, RS; Tan, LA; Todtenkopf, MS; White, M | 1 |
| Citrome, L; Faden, J; Serdenes, R | 1 |
| Corrao, MM; Nelson, LA | 1 |
| Gao, J; Li, J; Lu, X; Yang, J | 1 |
| Graham, C; Sun, L; von Moltke, L; Yagoda, S; Yao, B | 1 |
| Correll, CU; DiPetrillo, L; Du, Y; Graham, C; Hopkinson, C; Jiang, Y; Kahn, RS; McDonnell, D; Newcomer, JW; Silverman, B; Simmons, A | 1 |
| Buchanan, RW | 1 |
| Likhitsathian, S; Maneeton, B; Maneeton, N; Srisurapanont, M; Suttajit, S | 1 |
| Paik, J | 1 |
| Correll, CU; DiPetrillo, L; Kane, JM; Martin, W; Memisoglu, A; Silverman, BL | 1 |
| McDonnell, D; Sun, L; von Moltke, L | 1 |
| Correll, CU; DiPetrillo, L; Ehrich, EW; Jiang, Y; Martin, WF; Pathak, S; Silverman, BL; Weiden, PJ | 1 |
| Kumar, V; McDonnell, D; Sun, L; von Moltke, L; Yu, M | 1 |
| Cunningham, JI; Dean, RL; Deaver, DR; Eyerman, DJ; Namchuk, M; Sanchez, C; Todtenkopf, MS | 1 |
| Guloksuz, S; Reutenauer, EL; Srihari, VH; Tek, C | 1 |
| Ganguli, R; O'Malley, SS; Ratliff, J; Reutenauer, E; Tek, C | 1 |
| Howland, RH | 1 |
| Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH | 1 |
| Burnand, B; Nanchen, D; Peytremann-Bridevaux, I; Walther, MR; Willi, C | 1 |
| Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS | 1 |
| Kaplan, LM | 1 |
| Jatlow, P; Makuch, R; Meandzija, B; O'Malley, SS; Toll, BA; White, M; Wu, R | 1 |
| Borsook, D; Currie, PJ; Elman, I; Kurbanov, DB; Simonson, DC | 1 |
| Cai, X; Cao, D; deWit, H; King, AC; Kranzler, HR; Matthews, AK; O'Malley, SS; Stachoviak, RJ | 1 |
| Cao, D; King, AC; O'Malley, SS; Zhang, L | 1 |
| Corp, ES; Jones, JE | 1 |
| Chen, RZ; Fong, TM; Huang, RR; MacNeil, DJ; Shen, CP | 1 |
| Blakeslee, A; Cooney, JL; Cooney, NL; Dubin, JA; Jatlow, P; Krishnan-Sarin, S; Makuch, R; McKee, SA; Meandzija, B; O'Malley, SS; Romano-Dahlgard, D; Wu, R | 1 |
| McKee, SA; O'malley, SS; White, MA | 1 |
| Katulak, NA; O'Malley, S; Toll, BA; Williams-Piehota, P | 1 |
| Leary, V; Meandzija, B; O'Malley, SS; Salovey, P; Toll, BA; Wu, R | 1 |
| Shaw, WN | 1 |
| Alam, MY; Becker, JA; Goldman, MB; Luchins, DJ | 1 |
| Barocka, A; Kaschka, WP; Plaskacewicz, GJ; Rechlin, T; Wildt, L; Zimmermann, U | 1 |
| Lang, CM; McLaughlin, PJ; Tobias, SW; Zagon, IS | 1 |
| Acosta, A; Baptista, T; Colasante, C; de Mendoza, S; de Quijada, M; Hernández, L; Lacruz, A; Mendoza, JM | 1 |
8 review(s) available for naltrexone and Weight Gain
| Article | Year |
|---|---|
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine.
Topics: Analgesics, Opioid; Antipsychotic Agents; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Receptors, Opioid, kappa; Weight Gain | 2023 |
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Tablets; Weight Gain | 2022 |
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
Topics: Analgesics, Opioid; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Olanzapine; Schizophrenia; Weight Gain | 2022 |
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.
Topics: Antipsychotic Agents; Cardiometabolic Risk Factors; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Naltrexone; Olanzapine; Schizophrenia; Weight Gain | 2021 |
Olanzapine/Samidorphan: First Approval.
Topics: Antipsychotic Agents; Bipolar Disorder; Drug Combinations; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Weight Gain | 2021 |
Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Liraglutide; Melatonin; Naltrexone; Obesity; Psychotropic Drugs; Weight Gain | 2015 |
Practical Use of Pharmacotherapy for Obesity.
Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain | 2017 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; Ephedrine; Fenfluramine; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Weight Gain; Weight Loss | 2010 |
15 trial(s) available for naltrexone and Weight Gain
| Article | Year |
|---|---|
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Weight Gain; Young Adult | 2020 |
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Healthy Volunteers; Humans; Male; Naltrexone; Narcotic Antagonists; Olanzapine; Time Factors; Weight Gain; Young Adult | 2018 |
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chromatography, Liquid; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Olanzapine; Schizophrenia; Tandem Mass Spectrometry; Weight Gain | 2018 |
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
Topics: Adult; Antipsychotic Agents; Constipation; Dizziness; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Sleepiness; Weight Gain | 2019 |
A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Olanzapine; Rifampin; Weight Gain; Young Adult | 2019 |
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clinical Protocols; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Overweight; Psychotic Disorders; Research Design; Schizophrenia; Weight Gain; Weight Loss | 2013 |
A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cholesterol; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Pilot Projects; Psychotic Disorders; Quality of Life; Schizophrenia; Triglycerides; Weight Gain; Young Adult | 2014 |
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome; Weight Gain | 2010 |
Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial.
Topics: Administration, Cutaneous; Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Nicotine; Prospective Studies; Smoking; Smoking Cessation; Weight Gain | 2010 |
Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women.
Topics: Administration, Oral; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Sex Factors; Smoking Cessation; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome; Weight Gain | 2012 |
Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Sex Factors; Smoking Cessation; Treatment Outcome; Weight Gain | 2013 |
A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.
Topics: Administration, Cutaneous; Administration, Oral; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires; Treatment Outcome; Weight Gain | 2006 |
Smoke and mirrors: magnified beliefs that cigarette smoking suppresses weight.
Topics: Adult; Culture; Feeding Behavior; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Overweight; Psychiatric Status Rating Scales; Self Concept; Smoking; Smoking Cessation; Weight Gain | 2007 |
Validation of a scale for the assessment of food cravings among smokers.
Topics: Administration, Cutaneous; Appetite; Dietary Fats; Dietary Sucrose; Female; Food Preferences; Humans; Male; Naltrexone; Nicotine; Placebos; Reproducibility of Results; Smoking; Smoking Cessation; Surveys and Questionnaires; Taste; Weight Gain | 2008 |
Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: an open study.
Topics: Adult; Antidepressive Agents, Tricyclic; Appetite; Depressive Disorder; Female; Humans; Lithium; Middle Aged; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Weight Gain | 1997 |
13 other study(ies) available for naltrexone and Weight Gain
| Article | Year |
|---|---|
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Naltrexone; Narcotic Antagonists; Olanzapine; Schizophrenia; Weight Gain | 2022 |
Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Topics: Adult; Antipsychotic Agents; Cohort Studies; Drug Combinations; Drug Interactions; Female; Humans; Lithium Carbonate; Male; Naltrexone; Narcotic Antagonists; Olanzapine; Valproic Acid; Weight Gain; Young Adult | 2020 |
How Much of an Advance Is the Addition of Samidorphan to Olanzapine?
Topics: Antipsychotic Agents; Humans; Naltrexone; Olanzapine; Schizophrenia; Weight Gain | 2020 |
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Drug Combinations; Female; Glucose Metabolism Disorders; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Olanzapine; Rats; Rats, Sprague-Dawley; Sex Factors; Weight Gain | 2019 |
[Preventing weight gain in smoking cessation: there is no miracle solution].
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Fluoxetine; Humans; Naltrexone; Narcotic Antagonists; Patient Education as Topic; Risk; Selective Serotonin Reuptake Inhibitors; Smoking Cessation; Substance Withdrawal Syndrome; Weight Gain | 2009 |
Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats.
Topics: Animals; Antipsychotic Agents; Appetite Depressants; Appetite Regulation; Behavior, Animal; Benzodiazepines; Delayed-Action Preparations; Drug Interactions; Energy Intake; Feeding Behavior; Female; Injections, Intramuscular; Injections, Intraperitoneal; Leptin; Naltrexone; Narcotic Antagonists; Olanzapine; Random Allocation; Rats; Rats, Wistar; Weight Gain | 2012 |
Effect of naltrexone on food intake and body weight in Syrian hamsters depends on metabolic status.
Topics: Animals; Body Weight; Cricetinae; Drinking; Eating; Female; Male; Mesocricetus; Metabolism; Naltrexone; Narcotic Antagonists; Weight Gain | 2003 |
Chronic administration of nalmefene leads to increased food intake and body weight gain in mice.
Topics: Administration, Oral; Animals; Diet; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Eating; Energy Intake; Intubation, Gastrointestinal; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Receptors, Opioid; Time Factors; Weight Gain | 2004 |
A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.
Topics: Adult; Bupropion; Case-Control Studies; Combined Modality Therapy; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Smoking Cessation; Treatment Outcome; Weight Gain | 2008 |
Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants.
Topics: Albuterol; Animals; Appetite Depressants; Cyclohexanes; Dextroamphetamine; Drug Tolerance; Eating; Endorphins; Female; Fenfluramine; Injections, Subcutaneous; Male; Naltrexone; Obesity; Piperidines; Rats; Rats, Zucker; Weight Gain | 1993 |
Effects of naltrexone on mannerisms and water imbalance in polydipsic schizophrenics: a pilot study.
Topics: Adult; Antipsychotic Agents; Drinking; Drug Therapy, Combination; Humans; Hyponatremia; Male; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Stereotyped Behavior; Treatment Outcome; Water-Electrolyte Balance; Weight Gain | 1995 |
Opioid receptor blockade during prenatal life modifies postnatal behavioral development.
Topics: Animals; Behavior, Animal; Brain; Female; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Reflex; Weight Gain | 1997 |
Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats.
Topics: Animals; Antipsychotic Agents; Diestrus; Eating; Female; Hyperphagia; Naltrexone; Narcotic Antagonists; Obesity; Rats; Rats, Wistar; Sulpiride; Weight Gain | 2000 |